At a moment when antibiotic resistance is quietly becoming one of the defining medical challenges of the century, the University of Kansas has secured a major vote of confidence from the federal government. The National Institutes of Health has awarded KU $5.8 million to fund Phase 3 of its Chemical Biology of Infectious Disease center, known as CBID, an NIH Center of Biomedical Research Excellence that has been operating since 2016. The award is designed to do something that sounds simple but is remarkably difficult in practice: help a large, multi-institution research enterprise stand on its own feet financially once the federal COBRE scaffolding is removed. In the world of NIH-funded research centers, a Phase 3 award is the final stage of a deliberate arc, intended to set a center on a sustainable path beyond COBRE support at the federal level, ensuring that the scientific momentum built over a decade does not evaporate when the special funding mechanism ends.
The center’s mission is rooted in a deceptively straightforward observation about how modern science is organized. Infectious disease biologists at KU have long been skilled at identifying the gene products and factors that contribute to disease, mapping the molecular machinery that pathogens deploy to infect, evade and persist. Chemists and medicinal chemists, meanwhile, excel at developing chemical tools, probes and approaches that can interrogate and manipulate biological systems. Too often, Hefty noted, that expertise is not shared between the two camps. The CBID center was created precisely to bridge that divide, connecting infectious disease biologists with colleagues in chemistry, medicinal chemistry, pharmaceutical chemistry and bioengineering so that the identification of a disease-relevant target can be followed rapidly by the design of molecular tools to study and defeat it. As Hefty put it, both sides are good at what they do individually, but together is where they really excel.
What makes the Kansas effort notable is its scale and its reach across institutional boundaries. CBID recruits, mentors and supports investigators not only at the University of Kansas in Lawrence but also at KU Medical Center, Kansas State University, Wichita State University and other regional partners. The center gives participating researchers access to four core research labs organized around infectious disease high-throughput screening, computational chemical biology and molecular modeling, synthetic chemical biology and flow cytometry. These cores function as shared scientific infrastructure, allowing a researcher with a promising hypothesis but limited equipment to test it using capabilities that would be prohibitively expensive to build in an individual laboratory. Investigators can apply for pilot project funds and vouchers for low-barrier use of the core facilities, lowering the entry cost for exploratory science that might otherwise never get off the ground.
The center also invests heavily in something less tangible but arguably more important: bringing people together. Monthly programs and annual symposia create regular occasions for researchers from different departments and institutions to share results and swap ideas. You just have to get scientists in a room, sharing science, talking science, and great things come out of that, Hefty said, adding that collaborations and events often happen organically. Anyone who has watched interdisciplinary research struggle against the gravitational pull of departmental silos will recognize what the center is attempting. The most productive ideas in chemical biology frequently emerge at the boundaries between disciplines, where a biologist’s unmet need meets a chemist’s unexpected capability, and those encounters require deliberate cultivation.
The track record from the first two phases of funding offers evidence that the model works. Over its first decade, the center has recruited seven faculty members, contributed to 15 startups, and helped generate roughly $25 million in NIH funding along with $90 million from broader research projects, pilot projects and cores. Researchers affiliated with the center have authored more than 600 publications, and the scientific network now includes 80 affiliates. Those numbers matter beyond vanity metrics. Faculty recruitment supported by COBRE funding builds permanent intellectual capacity at a university, and the startup activity suggests that basic research at the center is feeding into the kind of translational pipeline that can eventually carry laboratory discoveries toward real-world applications against infectious disease.
Beyond the publications and the grant dollars, Hefty emphasized the center’s role in training and workforce development, a contribution he argued cannot be understated. Undergraduates, graduate students and postdocs have spent a decade learning techniques, tools and approaches in the center’s labs, and will continue to do so for at least another five years under the new award. Those trainees will disperse into professions across Kansas and beyond, carrying chemical biology skills into academia, industry and the biotechnology sector. In a state working to build a high-tech regional workforce, the center functions as an engine of human capital as much as a generator of papers. Hefty also credited the KU Office of Research, the College of Liberal Arts & Sciences and the Kansas Board of Regents for their support, and pointed to the School of Pharmacy and researchers at KU Medical Center in microbiology and biochemistry as key partners in the enterprise.
Scientifically, the Phase 3 era will be guided by the theme of fighting antibiotic resistance, and the strategy Hefty describes represents a meaningful departure from the traditional pharmaceutical playbook. Rather than pursuing broad-spectrum antibiotics, the center’s researchers will develop targeted treatments designed to protect the body’s beneficial microbiome while defeating resistance mechanisms. The logic is compelling. Conventional broad-spectrum antibiotics cannot distinguish between a pathogenic invader and the trillions of beneficial microbes that inhabit the human body, and the collateral damage they inflict on the microbiome has been linked to a range of secondary health problems, including opportunistic infections such as Clostridioides difficile. Hefty framed the ambition in concrete terms: if a patient has an infection with staph, strep or enterococcus, can researchers develop chemical tools, probes and approaches that target just those organisms without disrupting the rest of the flora in our bodies? And can new tools be developed to address the antibiotic resistance mechanisms that currently exist?
That question sits at the frontier of chemical biology, a field that uses small molecules as precision instruments for understanding and manipulating biological systems. Pathogen-selective compounds require an intimate knowledge of the biochemical differences between a pathogen and its human host, and between the pathogen and the harmless commensal bacteria that share the same ecological niche. Computational chemical biology and molecular modeling, one of the center’s four core capabilities, allow researchers to identify selective targets and predict how candidate molecules will interact with them. High-throughput screening can then test hundreds of thousands of compounds against those targets, while synthetic chemical biology provides the capacity to design and build new molecules from scratch. Flow cytometry, meanwhile, enables researchers to sort and analyze individual cells at high speed, a capability that is essential for studying heterogeneous bacterial populations and the emergence of resistant subpopulations within an infection.
The collaborative spirit underpinning the award will be on public display on October 16 and 17, when researchers and stakeholders gather for the fifth annual Chemical Biology Symposium at KU. The event is expected to draw more than 100 attendees, with regional participation from Kansas State and Wichita State. According to organizers, the symposium seeks to provide a forum for Graduate Training in Chemical Biology trainees and Chemical Biology of Infectious Disease researchers to present their work and to cover special topics with invited speakers. For Hefty, this cross-pollination of ideas among institutions, departments and disciplines is the whole point of the enterprise. We’re breaking down a lot of those disciplinary walls and barriers so that interdisciplinary science can occur and happen in a very productive way, he said.
Looking a decade ahead, Hefty described what success would look like: an established, formal research chemical biology center with the scientists recruited and supported over the years still participating in its activities. Such a center could continue to focus on infectious disease or expand into other areas, whether cancer, Alzheimer’s or neurological disorders, but the essential outcome would be a durable research structure that continues to support investigators at KU, KU Medical Center and other institutions. In an era when federal research funding is increasingly competitive and antibiotic resistance continues to outpace the development of new drugs, the Kansas experiment offers a test of whether deliberate, sustained investment in collaborative infrastructure can produce science that no single laboratory, department or discipline could achieve alone. With $5.8 million in new support and a decade of accumulated momentum, CBID now has the resources and the runway to find out.
Subject of Research: NIH Phase 3 COBRE funding for a chemical biology center addressing infectious disease and antibiotic resistance
Article Title: KU receives $5.8 million NIH Phase 3 COBRE funding for Chemical Biology of Infectious Disease center
Article References: KU receives $5.8 million NIH Phase 3 COBRE funding for Chemical Biology of Infectious Disease center. (n.d.). Original publication
Image Credits: AI Generated
DOI: Not provided
Keywords: University of Kansas, NIH, COBRE, chemical biology, infectious disease, antibiotic resistance, microbiome, drug discovery, high-throughput screening, molecular modeling, workforce development, interdisciplinary research
Cite Scienmag News
APA MLA Chicago
Drew Townsend. (September 26, 2026). University of Kansas Lands $5.8 Million NIH Grant to Fight Antibiotic Resistance. Scienmag. https://scienmag.com/university-of-kansas-lands-5-8-million-nih-grant-to-fight-antibiotic-resistance/
Drew Townsend. “University of Kansas Lands $5.8 Million NIH Grant to Fight Antibiotic Resistance.” Scienmag, 26 September 2026, https://scienmag.com/university-of-kansas-lands-5-8-million-nih-grant-to-fight-antibiotic-resistance/. Accessed 26 September 2026.
Drew Townsend. “University of Kansas Lands $5.8 Million NIH Grant to Fight Antibiotic Resistance.” Scienmag. September 26, 2026. https://scienmag.com/university-of-kansas-lands-5-8-million-nih-grant-to-fight-antibiotic-resistance/
Copy citation Download RIS
Tags: Antibiotic resistanceAntibiotic resistance researchchemical biologyChemical Biology of Infectious Disease centerCOBREcombating antibiotic-resistant pathogensdrug discoveryfederal support for infectious disease researchhigh-throughput screeninginfectious diseaseinterdisciplinary researchlong-term research funding strategiesmicrobiomemolecular mechanisms of infectious diseasesmolecular modelingNIHNIH grant for infectious diseasePhase 3 NIH funding for research centersscientific momentum in antibiotic resistancesustainable funding for NIH research centersUniversity of KansasUniversity of Kansas biomedical research fundinguniversity-led biomedical innovationWorkforce development
